Abstract library

10 results for "Gabe".
#1264 Efficacy and Safety of Sunitinib as Long-term Treatment in Japanese Patients with Advanced Pancreatic Neuroendocrine Tumors.
Introduction: The results from recent clinical trials have suggested the ethnical difference in antitumor activity of sunitinib against advanced pancreatic neuroendocrine tumors (PNET), which seemed to be higher in Japanese than those in Western patients.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Lingaku Lee
Authors: Lee L, Ueda K, Fujiyama T, Tachibana Y, ...
#1581 Evaluation of Somatostatin and Dopamine Receptor Subtype 2 Expression in Pancreatic Neuroendocrine Neoplasms
Introduction: Although somatostatin receptor subtype 2 (SSTR2) and dopamine type 2 receptor (D2R) are reported to be expressed in neuroendocrine neoplasms (NEN), there is a lack of data from studies on a large number of patients with pancreatic NEN.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Lingaku Lee
Authors: Lee L, Ito T, Kawabe K, Otsuka T, ...
#1582 Utility of Serum Chromogranin B Compared with Chromogranin A as a Biomarker in Japanese Patients with Pancreatic Neuroendocrine Tumors
Introduction: Currently, serum chromogranin A (CgA) is used as a biomarker for pancreatic neuroendocrine tumors (pNET); however, oral use of a proton pump inhibitor (PPI) and renal impairment can affect CgA.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Biomarkers
Presenting Author: Masami Miki
Authors: Miki M, Ito T, Hijioka M, Kawabe K, ...
#1688 Pancreatic NET-G3 Does Not Respond to Platinum-Based Chemotherapy: A Multicenter Study of Neuroendocrine Carcinomas
Introduction: Recent studies have shown that Pancreatic neuroendocrine carcinomas (NECs) contain well-differentiated NETs with high proliferative activity (WDNET-G3), as well as poorly differentiated NECs (PDNECs). Although patients with pNEC show variable responses to platinum-based chemotherapy, predictors of the response are unknown.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Ph.D. Susumu Hijioka
Authors: Hijioka S, Hosoda W, Matsuo K, Ueno M, ...
Keywords: NET G3, NEC, KRAS, Rb
#1699 Should the Selective Arterial Secretagogue Injection Test for Insulinoma Localization be Evaluated at 60 Seconds or At 120 Seconds?
Introduction: The selective arterial secretagogue injection (SASI) test is considered indispensable for an accurate insulinoma localization. The optimal timing of post-injection evaluation has not been established yet, as some studies recommend 60 seconds [SASI (60 sec)] while others support 120 seconds [SASI (120 sec)].
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Keijiro Ueda
Authors: Ueda K, Kawabe K, Lee L, Tachibana Y, ...
#2149 Symptomatic Hypothalamic-Pituitary Metastases Disclosing Malignant Paraganglioma
Introduction: A paraganglioma is a rare tumor composed of chromaffin cells. Malignant paraganglioma is a very rare presentation diagnosed by local recurrence after total resection of the primary mass or findings of distant metastasis. We report a case of a 34-year-old women with a Malignant paraganglioma presneting with visual loss and hypopituitarism resulting from metastasis to the pituitary area. The diagnosis of malignant paraganglioma was based on loco-regional and distant metastasis
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Case reports
Presenting Author: Aicha Bengueddach
#2153 Brain Metastasis Disclosing Neuroendocrine Tumor
Introduction: A paraganglioma is a rare tumor composed of chromaffin cells. Malignant paraganglioma is a very rare presentation diagnosed by local recurrence after total resection of the primary mass or findings of distant metastasis
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Case reports
Presenting Author: Aicha Bengueddach
#2703 Carcinoid Heart Disease: A Retrospective Study and a Multidisciplinary Proposal of a New Algorithm
Introduction: Development of carcinoid heart disease (CHD) is the major negative prognostic factor in patients with the carcinoid syndrome. The only effective treatment is valve replacement. However, the selection of candidates and determination of optimal timing remain unclear. Considerable variability in local treatment strategies exist
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Aicha Bengueddach
#2878 Surgical Management of Neuroendocrine Tumor-Associated Liver Metastases
Introduction: Liver metastasis is common among patients who suffer from neuroendocrine tumors (NETs). Radical surgery is the standard treatment whenever possible but there is still controversies concerning the treatment strategies such as resection of the primary, role of debulking surgery, liver transplantation (LT) and neoadjuvant or adjuvant therapies.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Aicha Bengueddach
#2962 90Y- and/or 177Lu-DOTATOC Re-Challenge in Patients with Progressive Neuroendocrine Tumors
Introduction: Most patients treated with PRRT will eventually progress. Previous studies indicated that repeated PRRT is feasible and promising.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. med. Susanne Aberle
Authors: Aberle S, Benz M, Grokovski R, Christ E, ...